Novartis' Afinitor Phase III trial demonstrates efficacy in delaying tumour growth

Switzerland-based Novartis has announced encouraging results from a pivotal Phase III trial demonstrating the efficacy of Afinitor (everolimus) tablets in significantly delaying tumour growth in HER2-positive advanced breast cancer.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news